Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BATM Advanced Communications in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 29.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in BATM Advanced Communications. This rating has held steady since May 2021, when it changed from a Buy consensus rating.
BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in Networking and Cyber, and Bio-Medical divisions. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization, carrier ethernet and MPLS access solutions, and cyber network monitoring. It also offers software services, such as training and technical support, laboratory service and maintenance; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.
Read More
